Survodutide: Dual GLP-1/Glucagon Agonist Research, MASH & Weight Studies

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

Survodutide represents a distinctive approach in the evolving landscape of multi-receptor metabolic peptides. While much of the recent research attention has focused on GLP-1/GIP dual agonists such as tirzepatide, survodutide takes a fundamentally different path by pairing GLP-1 receptor agonism with glucagon receptor agonism — a combination that initially appears counterintuitive but is supported by a growing body of clinical evidence. Developed by Boehringer Ingelheim under the research designation BI 456906, survodutide is currently in Phase 3 clinical trials for both obesity and metabolic dysfunction-associated steatohepatitis (MASH). This guide provides a comprehensive overview of survodutide’s mechanism, published clinical data, and position within the broader multi-agonist research landscape as of early 2026.

What Is Survodutide?

Survodutide, also referred to by its development code BI 456906, is a synthetic peptide classified as a dual GLP-1/glucagon receptor agonist. It was developed by Boehringer Ingelheim in collaboration with Zealand Pharma, which contributed the peptide engineering platform used in its design.

Unlike tirzepatide, which combines GLP-1 with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, survodutide replaces the GIP component with glucagon receptor agonism. This distinction is not merely academic — it reflects a fundamentally different hypothesis about how multi-receptor engagement can drive metabolic outcomes. The rationale centers on leveraging glucagon’s established role in energy expenditure and hepatic lipid metabolism, effects that GIP receptor agonism does not directly provide.

Survodutide is designed for once-weekly subcutaneous administration, consistent with the dosing frequency of other long-acting peptides in this class. Its molecular modifications include lipid conjugation to extend circulating half-life through albumin binding, and structural features that confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4).

As of early 2026, survodutide has not been approved by the FDA or any other regulatory authority. It is available exclusively as a research peptide for laboratory investigation. Survodutide is supplied by NorthPeptide for research purposes only.

Mechanism of Action: Dual GLP-1/Glucagon Receptor Agonism

Survodutide’s mechanism of action rests on the simultaneous activation of two receptor systems that, on the surface, appear to work at cross-purposes. Understanding why this combination is pharmacologically rational requires examining each receptor pathway individually and then considering how they interact.

GLP-1 Receptor Activation

The glucagon-like peptide-1 (GLP-1) receptor is expressed in the pancreas, brain, gastrointestinal tract, and other tissues. Activation of the GLP-1 receptor has been associated in research with several well-characterized downstream effects:

• Appetite suppression — GLP-1 receptor agonism in hypothalamic and brainstem centers has been observed to reduce food intake and promote satiety signaling in both preclinical and clinical studies.
• Glucose-dependent insulin secretion — GLP-1 receptor activation potentiates insulin release from pancreatic beta cells, but only in the presence of elevated blood glucose. This glucose-dependent mechanism reduces the risk of hypoglycemia compared to agents that stimulate insulin release regardless of glucose levels.
• Delayed gastric emptying — GLP-1 agonism slows the rate at which the stomach empties its contents into the small intestine, contributing to prolonged postprandial satiety and attenuated glucose excursions after meals.
• Beta-cell preservation — Preclinical research has suggested that GLP-1 receptor signaling may support pancreatic beta-cell survival and function, though the long-term significance of this observation in humans is still under investigation.

The GLP-1 component of survodutide provides the metabolic foundation that has been validated across multiple approved GLP-1 receptor agonists, including semaglutide and liraglutide.

Glucagon Receptor Activation

The inclusion of glucagon receptor agonism is what makes survodutide’s design intellectually provocative. Glucagon is classically understood as a counter-regulatory hormone that raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. Adding a glucose-raising component to a metabolic peptide appears counterintuitive — until the full spectrum of glucagon’s metabolic effects is considered.

Glucagon receptor activation, primarily in the liver but also in adipose tissue and other organs, mediates several metabolically significant pathways beyond glucose regulation:

• Increased energy expenditure — Glucagon receptor signaling has been associated in research with elevated resting energy expenditure (REE), potentially through activation of thermogenic pathways in brown adipose tissue and enhanced hepatic metabolic rate. This represents a weight loss mechanism fundamentally distinct from the appetite suppression provided by GLP-1 — rather than reducing energy intake, glucagon increases energy output.
• Hepatic fat oxidation — Glucagon receptor activation in hepatocytes directly stimulates the beta-oxidation of fatty acids and reduces de novo lipogenesis. This hepatic-specific effect has generated particular research interest in the context of MASH and metabolic-associated steatotic liver disease (MASLD), conditions characterized by pathological fat accumulation in the liver.
• Thermogenesis — Research has indicated that glucagon signaling promotes thermogenic activity, the process by which the body converts stored energy into heat rather than storing it as adipose tissue. This effect complements the energy expenditure pathway and may contribute to the body weight reduction observed in clinical trials.
• Amino acid metabolism — Glucagon receptor activation influences amino acid catabolism and ureagenesis in the liver, effects that may have implications for body composition research.

The Counterintuitive Logic: How the Dual Mechanism Works

The key insight underlying survodutide’s design is that the GLP-1 component effectively offsets the hyperglycemic effects of glucagon while allowing the non-glycemic benefits of glucagon receptor activation — energy expenditure, hepatic fat oxidation, and thermogenesis — to proceed. In published clinical data, survodutide has not been associated with clinically significant hyperglycemia, supporting the hypothesis that GLP-1-mediated insulin secretion and glucose regulation are sufficient to counterbalance glucagon’s glucose-raising activity.

This dual mechanism creates a two-pronged approach to metabolic research: GLP-1 reduces energy intake through appetite suppression and gastric emptying delay, while glucagon increases energy expenditure through thermogenesis and hepatic metabolic activation. The net result, as observed in clinical trials, is a metabolic equation that addresses both sides of the energy balance.

Research Applications Under Investigation

Survodutide is being investigated across multiple research domains that reflect the broad metabolic impact of dual GLP-1/glucagon receptor agonism:

• Obesity and body weight regulation — The primary research application, with Phase 3 trials investigating survodutide’s effects on body weight reduction in adults with obesity. The dual energy intake reduction (via GLP-1) and energy expenditure increase (via glucagon) provides a mechanistic rationale for enhanced weight loss beyond what single-agonist approaches achieve.
• Metabolic dysfunction-associated steatohepatitis (MASH) — Boehringer Ingelheim is actively pursuing a MASH indication for survodutide, based on Phase 2b data showing significant liver fat reduction and MASH resolution. The glucagon receptor component’s direct effects on hepatic lipid metabolism make survodutide a mechanistically compelling candidate for liver disease research.
• Hepatic lipid metabolism and MASLD — Beyond MASH specifically, survodutide’s effects on liver fat content are being investigated in the broader context of metabolic-associated steatotic liver disease (MASLD), reflecting the growing recognition that hepatic steatosis exists on a spectrum of disease severity.
• Energy expenditure and thermogenesis research — The glucagon receptor component has prompted investigation into whether survodutide measurably increases resting energy expenditure through indirect calorimetry, a question with implications for understanding the mechanistic contributions of each receptor pathway.
• Glycemic regulation — Despite the glucagon component’s glucose-raising potential, survodutide’s net effect on glycemic parameters is under investigation, with early data suggesting that the GLP-1 component provides sufficient glycemic control to offset glucagon-mediated glucose elevation.

Clinical Trial Data

Survodutide has progressed through Phase 1 and Phase 2 clinical trials, with Phase 3 trials currently underway. The following summarizes published and reported clinical findings as of early 2026.

Phase 2 Obesity Trial Results

The pivotal Phase 2 trial of survodutide in adults with obesity was a randomized, double-blind, placebo-controlled study that evaluated multiple dose levels over a 46-week treatment period. Key findings included:

• Body weight reduction of 18-19% — Participants receiving the highest doses of survodutide achieved mean body weight reductions of approximately 18-19% at 46 weeks, compared to placebo. This magnitude of weight loss positioned survodutide competitively among the multi-receptor agonists in clinical development.
• Dose-dependent response — A clear dose-response relationship was observed, with higher dose cohorts demonstrating greater body weight reductions, consistent with the pharmacological profile of a receptor-mediated mechanism.
• Consistent weight trajectory — Weight loss continued throughout the 46-week study period at the higher doses studied, without evidence of a plateau, suggesting that sustained receptor engagement maintains ongoing metabolic effects.

These Phase 2 results were presented at major metabolic research conferences and provided the basis for Boehringer Ingelheim’s decision to advance survodutide into Phase 3 trials.

Phase 2b MASH Trial Results

Perhaps the most compelling clinical data for survodutide has come from the Phase 2b trial investigating its effects in patients with biopsy-confirmed MASH. This trial represented a critical step in evaluating whether survodutide’s glucagon-mediated hepatic effects translate to clinically meaningful outcomes in liver disease. Key findings included:

• Significant liver fat reduction — Survodutide demonstrated substantial reductions in hepatic fat content as measured by imaging-based assessments, consistent with the hypothesized mechanism of glucagon receptor-driven hepatic fat oxidation.
• MASH resolution — A significant proportion of subjects achieved histological resolution of MASH, defined as the absence of steatohepatitis on liver biopsy without worsening of fibrosis. MASH resolution is considered a key regulatory endpoint and a meaningful clinical outcome in liver disease research.
• Fibrosis improvement signals — Early data suggested potential improvements in liver fibrosis staging, though fibrosis endpoints require longer follow-up periods for definitive assessment.

Based on these Phase 2b results, Boehringer Ingelheim has advanced survodutide into Phase 3 trials for MASH, positioning it alongside resmetirom (the only FDA-approved treatment for MASH as of early 2026) and other investigational agents in this rapidly evolving therapeutic area.

Phase 3 Program (Ongoing)

Survodutide is currently in Phase 3 clinical development for both obesity and MASH indications. The Phase 3 program includes multiple trials designed to confirm the Phase 2 efficacy and safety findings in larger, more diverse patient populations. Specific Phase 3 trial details include:

• Obesity Phase 3 trials — Large-scale, randomized, placebo-controlled studies in adults with obesity, with body weight reduction as the primary endpoint and cardiometabolic secondary endpoints.
• MASH Phase 3 trials — Biopsy-confirmed MASH populations with histological endpoints, including MASH resolution and fibrosis improvement. These trials represent Boehringer Ingelheim’s active pursuit of a MASH indication alongside the obesity program.

Full Phase 3 results are anticipated over the course of 2026-2027, with regulatory submissions expected to follow positive outcomes. As of early 2026, survodutide remains an investigational compound with no regulatory approvals.

Multi-Agonist Comparison: Survodutide in Context

The metabolic peptide research landscape has rapidly expanded from single-receptor agonists to multi-receptor approaches. Placing survodutide in context with other multi-agonist peptides highlights both its unique mechanism and the broader strategic differences among approaches in clinical development.

Feature	Semaglutide	Tirzepatide	Survodutide	Cagrilintide + Semaglutide	Retatrutide
Classification	Single agonist	Dual agonist	Dual agonist	Combination therapy	Triple agonist
Receptor Targets	GLP-1	GLP-1 + GIP	GLP-1 + Glucagon	GLP-1 + Amylin	GLP-1 + GIP + Glucagon
Developer	Novo Nordisk	Eli Lilly	Boehringer Ingelheim	Novo Nordisk	Eli Lilly
Energy Expenditure via GCGR	No	No	Yes	No	Yes
Hepatic Fat Oxidation via GCGR	No	No	Yes	No	Yes
Body Weight Reduction (Phase 2)	~15-17%	~20-22%	~18-19%	~22% (CagriSema)	~24%
MASH/Liver Fat Focus	Limited data	SURPASS-PNPLA3 ongoing	Phase 3 for MASH	Not primary	Strong Phase 2a data
Regulatory Status (2026)	FDA-approved	FDA-approved	Phase 3 trials	Phase 3 trials	Phase 3 trials

Several observations emerge from this comparison:

• Survodutide vs. tirzepatide — Both are dual agonists, but they pair GLP-1 with different secondary targets. Tirzepatide adds GIP receptor agonism, which potentiates insulin secretion and influences lipid metabolism in adipose tissue. Survodutide adds glucagon receptor agonism, which drives energy expenditure and hepatic fat oxidation. These represent fundamentally different hypotheses about the most beneficial second receptor to engage.
• Survodutide vs. retatrutide — Retatrutide is a triple agonist that combines all three receptors: GLP-1, GIP, and glucagon. In some respects, retatrutide can be viewed as encompassing survodutide’s mechanism (GLP-1 + glucagon) with the addition of GIP. Retatrutide’s Phase 2 data showed higher weight loss (~24%), potentially reflecting the additive benefit of the third receptor, though direct comparison is complicated by differences in trial design and dosing.
• The glucagon advantage for liver disease — Survodutide’s glucagon receptor component gives it a distinctive profile for MASH research. The direct hepatic effects of glucagon receptor activation — stimulating fat oxidation and reducing lipogenesis in the liver — provide a mechanism-based rationale for liver disease investigation that GLP-1/GIP agonists lack. This has led Boehringer Ingelheim to pursue MASH as a co-primary indication alongside obesity.
• Cross-trial limitations — As with all cross-trial comparisons, differences in study populations, endpoints, dose escalation protocols, and trial duration prevent definitive ranking of these agents. Head-to-head studies would be required for rigorous efficacy comparisons.

Related research peptides available for laboratory investigation: Cagrilintide | Mazdutide

Dosing in Research Protocols

Published clinical trials have employed the following general approach to survodutide dosing, which is relevant context for researchers designing laboratory protocols:

• Administration route — Subcutaneous injection, consistent with other long-acting peptide agonists in this class.
• Dosing frequency — Once weekly, supported by the peptide’s extended half-life achieved through lipid conjugation and albumin binding.
• Dose escalation — Clinical trials have employed gradual dose escalation protocols, starting at lower doses and titrating upward over several weeks. This approach has been used across the multi-agonist class to mitigate gastrointestinal side effects during the initial exposure period. Rapid dose escalation has been associated with higher rates of nausea and vomiting in published studies of GLP-1-based peptides.
• Dose range studied — Phase 2 trials evaluated multiple dose levels, with the highest doses producing the greatest body weight reductions. Specific dose levels and escalation schedules are detailed in published trial protocols.

For researchers working with survodutide in laboratory settings, standard peptide handling protocols apply. Lyophilized peptide should be stored at -20°C and protected from light. Reconstitution should be performed with bacteriostatic water or sterile saline according to the supplier’s specifications. Reconstituted solutions should be refrigerated at 2-8°C and used within the timeframe indicated by the manufacturer. Repeated freeze-thaw cycles should be avoided to preserve peptide integrity.

Safety Profile Observed in Research

Across published Phase 1 and Phase 2 data, the safety profile of survodutide has been characterized as generally consistent with the class effects observed for GLP-1-based peptide agonists, with certain considerations specific to the glucagon receptor component.

Gastrointestinal Effects

The most commonly reported adverse events in clinical trials have been gastrointestinal in nature, consistent with the class effects of GLP-1 receptor agonists:

• Nausea — The most frequently reported adverse event, with incidence rates that were dose-dependent and generally highest during the dose-escalation period.
• Vomiting and diarrhea — Reported at lower frequencies than nausea, generally mild to moderate in severity, and tending to resolve with continued exposure.
• Decreased appetite — Observed across active treatment groups, consistent with the intended GLP-1-mediated satiety effect.
• Constipation — Reported in some subjects, consistent with the gastric emptying delay associated with GLP-1 receptor agonism.

Gastrointestinal effects were most pronounced during the dose-escalation phase and tended to attenuate with continued treatment, a pattern observed consistently across the GLP-1 agonist class.

Glucagon-Specific Considerations

The inclusion of glucagon receptor agonism introduces safety considerations that do not apply to GLP-1-only or GLP-1/GIP agonists:

• Glycemic effects — The theoretical concern that glucagon receptor agonism would raise blood glucose has been a central question in survodutide’s clinical development. Published data has not demonstrated clinically significant hyperglycemia in survodutide-treated subjects, supporting the hypothesis that concurrent GLP-1 receptor activation provides sufficient glycemic counter-regulation. However, glycemic monitoring remains an important component of ongoing trials.
• Heart rate effects — GLP-1 receptor agonists have been associated with modest increases in heart rate in clinical studies. Whether the addition of glucagon receptor agonism modifies this effect is under investigation.
• Hepatic effects — While the glucagon receptor component’s hepatic fat oxidation effects are a therapeutic rationale for MASH, long-term hepatic safety monitoring is ongoing in Phase 3 trials.

Discontinuation and Tolerability

Discontinuation rates due to adverse events in Phase 2 trials were reported at levels consistent with other peptides in the multi-agonist class. The use of dose-escalation protocols appeared to improve overall tolerability. Long-term safety data beyond the Phase 2 trial duration will be provided by the ongoing Phase 3 program.

Areas Requiring Further Investigation

• Long-term safety — Multi-year exposure data from the Phase 3 program will be essential for characterizing the long-term safety profile of dual GLP-1/glucagon agonism.
• Cardiovascular outcomes — Whether survodutide’s metabolic effects translate to cardiovascular event reduction is a question that may require dedicated cardiovascular outcomes trials.
• Special populations — Safety data in renally impaired, hepatically impaired, elderly, and pediatric populations remains limited or is being collected in ongoing studies.
• Gallbladder events — As with other GLP-1-based peptides, cholelithiasis and cholecystitis-related events are being monitored in clinical trials, as rapid weight loss is an established risk factor for gallstone formation.

Researchers should note that all safety data to date derives from controlled clinical trial settings with specific inclusion and exclusion criteria, and may not represent the full range of observations in broader populations.

Summary

Survodutide (BI 456906) occupies a distinctive position in the multi-receptor agonist landscape by pairing GLP-1 receptor agonism with glucagon receptor agonism rather than the GIP receptor agonism used by tirzepatide. This design reflects the hypothesis that glucagon’s effects on energy expenditure, hepatic fat oxidation, and thermogenesis — when counterbalanced by GLP-1’s glycemic regulation — can produce meaningful metabolic outcomes through a mechanistically differentiated pathway.

Published Phase 2 data supports this hypothesis, with approximately 18-19% body weight reduction at 46 weeks and significant MASH-related improvements in liver fat and histological endpoints. The Phase 2b MASH results have been particularly notable, positioning survodutide as one of a small number of investigational agents with strong mechanism-based rationale and clinical evidence for hepatic metabolic disease.

Phase 3 trials are currently underway for both obesity and MASH indications, with results anticipated over 2026-2027. The safety profile observed in clinical trials to date has been generally consistent with the GLP-1 agonist class, with the glucagon component’s theoretical glycemic concerns not manifesting as clinically significant hyperglycemia in published data.

For researchers investigating multi-agonist metabolic peptides, survodutide’s dual GLP-1/glucagon mechanism offers a complementary research angle to the GLP-1/GIP approach of tirzepatide and the triple agonism of retatrutide. The question of which receptor combination produces optimal outcomes across different metabolic conditions — obesity, MASH, diabetes, cardiovascular disease — remains one of the most actively investigated questions in metabolic peptide research.

Related research guides: Retatrutide Research Guide | Semaglutide Research Guide | Tirzepatide Research Guide | Cagrilintide Research Guide

Research peptide: Survodutide | Related: Retatrutide | Cagrilintide | Mazdutide

---

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Zimmermann et al.	2022	Research	BI 456906 discovery and preclinical dual agonist pharmacology	PMC9679702
Wan et al.	2024	Meta-Analysis	Survodutide weight loss effect in randomized trials	PMC11542446
Wharton et al.	2025	Trial Design	SYNCHRONIZE phase 3 trials rationale and design	PMC11664303
Blüher et al.	2024	Clinical Trial	Phase 2 dose-finding trial for obesity	PMID 38330987
Sanyal et al.	2024	Clinical Trial	Phase 2 randomized trial of survodutide in MASH and fibrosis	PMID 38847460
Nauck et al.	2024	Clinical Trial	Survodutide dose-response on HbA1c and body weight in T2D	PMC10844353
Hartman et al.	2024	Research	Survodutide pharmacokinetics in cirrhosis	PMID 38857788
Gao et al.	2024	Review	Survodutide novel peptide for obesity and metabolic diseases	PMC12184103